jueves, 31 de enero de 2019

HP&M’s Anne Walsh to Present on Pharmacovigilance & Drug Safety Issues

HP&M’s Anne Walsh to Present on Pharmacovigilance & Drug Safety Issues

Link to FDA Law Blog

Posted: 30 Jan 2019 05:09 PM PST
Hyman, Phelps & McNamara, P.C. is pleased to announce that Anne Walsh will present at this year’s Pharmacovigilance & Drug Safety: Risk Management & Regulatory Compliance Conference, to be held in Arlington, VA on March 12-13, 2019.   The focus of her presentation is on post-market approaches to drug safety, such as adverse event reporting and mandated studies.  She will speak to Agency initiatives and research surrounding post-market safety issues, methods used to determine causal relationships, and tools FDA uses to address safety concerns.

Other topics to be addressed at the conference include:

  • Risk-Based Approaches to Signal Detection & Surveillance
  • Supporting Clearance through Proactive Safety in Clinical Research
  • Drug Safety Monitoring in the Post-Approval Environment
  • Use of Real-World Data to Support Long-Term Product Safety
  • Transforming Safety from National to Global Safety Surveillance
  • Technology & Automation in the Future of Pharmacovigilance
Attendee registration is limited to professionals from pharmaceutical and biotech companies.

FDA Law Blog readers can receive $200 off the event price using the promo code FDALAWBLOG.  Please register on this page.

No hay comentarios:

Publicar un comentario